Moreover, Ma et al. revealed that bispecific antibodies that simultaneously target YKL-40 and PD-1 have impressive synergistic antitumor effects, inducing CD8+, perforin+, and granzyme+ cytotoxic T cells and generating tumor cytotoxicity [60]. The gene discussed is PRF1; the disease is neoplasm.